XM non fornisce servizi ai residenti degli Stati Uniti d'America.

XM non fornisce servizi ai residenti degli Stati Uniti d'America.
S
S

Stryker

News

Reuters - 1 giorno fa

Stryker Completes Acquisition Of Artelon

BRIEF-Stryker Completes Acquisition Of Artelon July 15 (Reuters) - Stryker Corp SYK.N : STRYKER COMPLETES ACQUISITION OF ARTELON, INC. Source text for Eikon: ID:nBw2Q55RHa Further company coverage: SYK.N
S
Reuters - 2 settimane fa

Smith & Nephew faces long and painful activist fix

BREAKINGVIEWS-Smith & Nephew faces long and painful activist fix The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, July 4 (Reuters Breakingviews) - Smith & Nephew SN.L should prepare for a long and painful activist treatment. On Thursday, Swedish investor Cevian Capital announced it had taken a 5% stake in the $11 billion UK-listed maker of hip joints and wound care kit.
U
S
Reuters - 2 settimane fa

Masimo COO Muhsin to resign if activist investor Politan takes control

UPDATE 2-Masimo COO Muhsin to resign if activist investor Politan takes control Adds background throughout July 1 (Reuters) - Masimo MASI.O Chief Operating Officer Bilal Muhsin has told the board he would resign if activist investor Politan Capital Management takes control of the company and CEO Joe Kiani is removed, according to a regulatory filing.
A
S
Reuters - 2 mesi fa

Masimo prepared to provide one board seat if activist Politan drops proxy contest

UPDATE 4-Masimo prepared to provide one board seat if activist Politan drops proxy contest Adds Politan's response in paragraph 4, 6, 8 and 9 By Christy Santhosh and Pratik Jain May 9 (Reuters) - Masimo MASI.O said on Thursday that it is prepared to appoint Politan Capital Management's nominee William Jellison as a director on its board, if the activist investor withdraws its other nominee and drops its proxy contest.
A
S
Reuters - 3 mesi fa

Baxter raises annual profit forecast on strong demand for medical devices

REFILE-Baxter raises annual profit forecast on strong demand for medical devices Corrects to add story keyword used by media customers May 2 (Reuters) - Medical device maker Baxter International BAX.N raised its annual profit forecast and beat quarterly estimates on Thursday, banking on strong demand for its infusion pumps and dialysis products. Investor expectations around the performance of medical device makers have been heightened since last November due to higher demand for procedures, espe
A
S
Reuters - 3 mesi fa

Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices

Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices May 2 (Reuters) - Medtech firm Zimmer Biomet Holdings ZBH.N beat Wall Street estimates for first-quarter profit on Thursday, on the back of robust demand for its devices that are used in knee and hip reconstruction procedures. Zimmer's results extend a strong quarter for medical device makers, including peer Stryker Corp SYK.N which raised its annual profit outlook betting on steady demand for its hip and knee implant
S
Z
Reuters - 3 mesi fa

Teleflex beats quarterly profit estimates on healthy demand for medical devices

Teleflex beats quarterly profit estimates on healthy demand for medical devices May 2 (Reuters) - Teleflex TFX.N reported a better-than-expected first-quarter profit on Thursday, on the back of strong demand for its medical devices. The Wayne, Pennsylvania-based company also raised the lower end of its 2024 adjusted profit forecast to $13.60 from $13.55 per share, keeping the upper end at $13.95 per share.
S
T
Reuters - 3 mesi fa

Stryker lifts 2024 profit forecast on strong demand for medical devices, implants

REFILE-Stryker lifts 2024 profit forecast on strong demand for medical devices, implants Adds media packaging code April 30 (Reuters) - Stryker Corp SYK.N lifted its full-year profit forecast on Tuesday, owing to resilient demand for the company's medical devices and implants. The joint-implant maker now sees its annual profit per share to be between $11.85 and $12.05, raised from the previous range of between $11.70 and $12. The analysts' average estimate for 2024 is pegged at $11.85 per share.
S
Reuters - 3 mesi fa

Stryker Corp reports results for the quarter ended in March - Earnings Summary

Stryker Corp reports results for the quarter ended in March - Earnings Summary Stryker Corp SYK.N reported quarterly adjusted earnings of $2.50​​ per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $2.14. The mean expectation of twenty six analysts for the quarter was for earnings of $2.35 per share.
S
Reuters - 3 mesi fa

Stryker Q1 Adjusted EPS USD 2.5 Vs. IBES Estimate USD 2.35

BRIEF-Stryker Q1 Adjusted EPS USD 2.5 Vs. IBES Estimate USD 2.35 Apr 30 (Reuters) - Stryker Q1 revenue USD 5,200 million vs. IBES estimate USD 5,103 million. Q1 adjusted gross margin 63.6% Q1 EPS USD 2.05 Q1 adjusted EBIT margin 21.9% Q1 net income USD 788 million Q1 adjusted net income USD 962 million vs. IBES estimate USD 903.3 million outlook FY
S
Reuters - 3 mesi fa

Yen slips anew with Amazon due, Treasury plans irk

MORNING BID AMERICAS-Yen slips anew with Amazon due, Treasury plans irk A look at the day ahead in U.S. and global markets from Mike Dolan World markets stalled on Tuesday as another heavy earnings week for megacap stocks cranked up, with renewed slippage in Japan's yen and U.S. Treasuries eyed closely in the background. Major macro market moves are likely in check for now as the Federal Reserve starts its latest two day policy meeting - with Wall Street also eyeing first quarter results from tw
A
A
E
H
I
M
P
S
S
T
U
A
J
U
E
E
I
S
M
Reuters - 3 mesi fa

Stryker Corp <SYK.N> expected to post earnings of $2.36 a share - Earnings Preview

Stryker Corp expected to post earnings of $2.36 a share - Earnings Preview Stryker Corp SYK.N , SYK is expected to show a rise in quarterly revenue when it reports results on April 30 for the period ending March 31 2024 The Kalamazoo Michigan-based company is expected to report a 6.8% increase in revenue to $5.103 billion from $4.78 billion a year ago, according to the mean estimate from 22 analysts, based on LSEG data.
S
Reuters - 3 mesi fa

Medical device makers fall after J&J's medtech unit misses sales estimates

BUZZ-Medical device makers fall after J&J's medtech unit misses sales estimates ** Shares of medical device makers fall between 1% and 3% after Johnson & Johnson's JNJ.N medical devices unit reports Q1 sales of $7.82 bln, missing Wall Street estimates of $7.88 bln, per LSEG data ** Stryker SYK.N down 1%, Zimmer Biomet ZBH.N down 1.2%, Medtronic MDT
A
B
S
Z
Reuters - 3 mesi fa

J&J's medical device sales fall short, cancer drugs seen growing

UPDATE 5-J&J's medical device sales fall short, cancer drugs seen growing Recasts with focus on medical device sales miss, Adds investor call details in paragraphs 8-10 and 17, updates shares By Patrick Wingrove and Bhanvi Satija April 16 (Reuters) - Johnson & Johnson's JNJ.N first-quarter revenue missed Wall Street estimates for medical devices on Tuesday and sales of its blockbuster psoriasis drug Stelara came in lower than expected as the company prepares for its loss of exclusivity in the U.
S
Z

Condizioni

Asset popolari

Disclaimer: le entità di XM Group forniscono servizi di sola esecuzione e accesso al nostro servizio di trading online, che permette all'individuo di visualizzare e/o utilizzare i contenuti disponibili sul sito o attraverso di esso; non ha il proposito di modificare o espandere le proprie funzioni, né le modifica o espande. L'accesso e l'utilizzo sono sempre soggetti a: (i) Termini e condizioni; (ii) Avvertenza sui rischi e (iii) Disclaimer completo. Tali contenuti sono perciò forniti a scopo puramente informativo. Nello specifico, ti preghiamo di considerare che i contenuti del nostro servizio di trading online non rappresentano un sollecito né un'offerta ad operare sui mercati finanziari. Il trading su qualsiasi mercato finanziario comporta un notevole livello di rischio per il tuo capitale.

Tutto il materiale pubblicato sul nostro servizio di trading online è unicamente a scopo educativo e informativo, e non contiene (e non dovrebbe essere considerato come contenente) consigli e raccomandazioni di carattere finanziario, di trading o fiscale, né informazioni riguardanti i nostri prezzi di trading, offerte o solleciti riguardanti transazioni che possano coinvolgere strumenti finanziari, oppure promozioni finanziarie da te non richieste.

Tutti i contenuti di terze parti, oltre ai contenuti offerti da XM, siano essi opinioni, news, ricerca, analisi, prezzi, altre informazioni o link a siti di terzi presenti su questo sito, sono forniti "così com'è", e vanno considerati come commenti generali sui mercati; per questo motivo, non possono essere visti come consigli di investimento. Dato che tutti i contenuti sono intesi come ricerche di investimento, devi considerare e accettare che non sono stati preparati né creati seguendo i requisiti normativi pensati per promuovere l'indipendenza delle ricerche di investimento; per questo motivo, questi contenuti devono essere considerati come comunicazioni di marketing in base alle leggi e normative vigenti. Assicurati di avere letto e compreso pienamente la nostra Notifica sulla ricerca di investimento non indipendente e la nostra Informativa sul rischio riguardante le informazioni sopra citate; tali documenti sono consultabili qui.

Avvertenza sul rischio: Il tuo capitale è a rischio. I prodotti con leva finanziaria possono non essere adatti a tutti. Ti chiediamo di consultare attentamente la nostra Informativa sul rischio.